📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines (2020)

First Author: Agache I

Attributed to: Cutaneous Immunology funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/all.14547

PubMed Identifier: 32767573

Publication URI: http://europepmc.org/abstract/MED/32767573

Type: Journal Article/Review

Parent Publication: Allergy

Issue: 1

ISSN: 0105-4538